Why the study?
Does intensive blood-pressure control (target systolic blood pressure <120 mm Hg) reduce the incidence of cardiovascular events in patients with type 2 diabetes?
Does intensive blood-pressure control (target systolic blood pressure <120 mm Hg) reduce the incidence of cardiovascular events in patients with type 2 diabetes?
This letter to the editor questions the feasibility and cardiovascular benefit of a systolic blood pressure target <120 mm Hg in patients with type 2 diabetes, noting it was achieved in only ~60% of the intensive-treatment group in the BPROAD trial.
To the Editor: In the Blood Pressure Control Target in Diabetes (BPROAD) trial, Bi et al. (March 27 issue) 1 used the classic design of a prospective randomized trial with an intention-to-treat analysis. However, the target systolic blood pressure of less than 120 mm Hg was met in only approximately 60% of the patients in the intensive-treatment group. In an outcome research study in which the relationship between the blood pressure at study entry and future cardiovascular outcomes was examined, a systolic blood pressure of less than 120 mm Hg provided no benefit with respect to the incidence of cardiovascular events . . .
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: